OCC

ORTHOCELL FPO [OCC]
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for nerve, tendon, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Healthcare · ASX Small Cap
$0.7150 -0.7%

Updated 22 Jul 2026 · Signals refresh every scan

Get alerts when OCC triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track OCC — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is losing steam
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Sitting near support — this level has held before and could attract buyers again
  • Drifting lower — down 5.9% over the last 5 days
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Strong cash runway (15 quarters)
  • Strong revenue growth (+49%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (2% of range)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +49% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.46%/day)
  • Beneish M-Score -1.97 (grey zone -2.22 to -1.78): possible earnings manipulation
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 2d (+5pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-134%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 36% over the past year
Ask Scout AI about OCC
"What's driving OCC today?" "How does OCC compare to peers?" "Key risks for OCC?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Appendix 3Y - John Van Der Wielen
NONE Application for quotation of securities - OCC
NONE Appendix 3Y x 4

Recent ASX Announcements

2026-07-20 Appendix 3Y - John Van Der Wielen
2026-07-20 Application for quotation of securities - OCC
2026-07-17 Appendix 3Y x 4
2026-07-17 Application for quotation of securities - OCC
2026-07-17 Notification regarding unquoted securities - OCC

Key Metrics

$194.7M
Market Cap
518K
Avg Volume
0.8x
Vol Ratio
$0.70 — $1.60
52-Week Range
0.4%
Short Interest
N/A
Cash Runway
-41.1%
ROE
-133.8%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 84%
LLeader vs LaggardlaggardRS: -9
IInstitutional SponsorshipweakInst: 2%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:OCC vs IDTOCC vs ADROCC vs LDX
Scout Pro — Deeper Analysis for OCC
Try Pro free for 30 days
Share this analysis

Track OCC and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required